GlassScriptPhysician profile
Renee Roth
NPI 1295975266
$8,561.38
in general payments reported to CMS, 2019-2025
62 companies · $495 in 2025
The $495 reported for 2025 was more than what 76% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $610 · 2022: $1,565 · 2023: $3,242 · 2024: $2,648 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,307 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,307.41 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $704.81 | 2021-2025 | Keytruda, Welireg, Reblozyl |
| Novartis Pharmaceuticals Corporation | $558.56 | 2021-2025 | |
| Janssen Biotech, INC. | $539.02 | 2022-2025 | Imbruvica, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $498.69 | 2021-2024 | Enhertu, Injectafer |
| Exelixis INC. | $393.99 | 2021-2024 | Cabometyx |
| Celgene Corporation | $393.31 | 2021-2025 | Pomalyst, Opdualag, Reblozyl |
| Lilly USA, LLC | $381.77 | 2021-2024 | Retevmo, Jaypirca, Verzenio |
| Abbvie INC. | $374.67 | 2023-2025 | |
| Incyte Corporation | $313.52 | 2022-2024 | Jakafi, Pemazyre, Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $311.85 | 2021-2023 | Imbruvica, Epkinly |
| Genzyme Corporation | $291.49 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $265.28 | 2021-2024 | Tagrisso, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $208.82 | 2022-2024 | Iclusig, Fruzaqla, Alunbrig |
| Tersera Therapeutics LLC | $190.29 | 2021-2024 | Zoladex |
| Glaxosmithkline, LLC. | $190.21 | 2023-2025 | Ojjaara, Zejula, Jemperli |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.